Putting caution in TEAM: High-dose chemotherapy with autologous HSCT for primary central nervous system lymphoma

Bone Marrow Transplantation

Volumn 47, Issue 10, 2012, Pages 1383-1384

  Tombleson, R L ^a   Green, M R ^b,c   Fancher, K M ^d,e  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

^d West Penn Allegheny Oncology Network   (United States)

^e WESTERN PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN; METHOTREXATE; THIOTEPA;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; COMORBIDITY; DRUG MEGADOSE; HUMAN; LETTER; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; STEM CELL TRANSPLANTATION;

EID: 84867400658     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.48     Document Type: Letter

References (10)

1. Reddy N, Savani BN. Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCT. Bone Marrow Transplant 2012; 47: 1265-1268.
2. Campen CJ, Tombleson RL, Green MR. High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma. J Neurooncol 2011; 101: 345-355.
3. Montemurro M, Kiefer T, Schüler F, Al-Ali HK, Wolf HH, Herbst R et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hämato-Onkologie OSHO-53 phase II study. Ann Oncol 2007; 18: 665-671.
4. Alimohamed N, Daly A, Owen C, Duggan P, Stewart DA. Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. Leuk Lymphoma 2012; 53: 862-867.
5. Cote GM, Hochberg EP, Muzikansky A, Hochberg FH, Drappatz J, McAfee SL et al. Autologous stem cell transplantation with thiotepa, busulfan and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2012; 18: 76-83.
6. Ferreri AJM, Crocchiolo R, Assanelli A, Govi S, Reni M. High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma 2008; 49: 2042-2047.
7. Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003; 21: 4151-4156.
8. Brevet M, Garidi R, Grunson B, Royer B, Vaida I, Damaj G. First-line autologous stem cell transplantation in primary CNS lymphoma. Eur J Haematol 2005; 75: 288-292.
9. Carella AM, Palumbo G, Merla E, Ferrara F, Greco M, Dell'Olio M et al. TEAM (thiotepa, etoposide, cytarabine, melphalan) as conditioning regimen for lymphoma treatment with autologous haematopoietic stem cell transplantation. Haematologica 2009; 94(Suppl 2): 66 (abstract 0172).
10. Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 2008; 14: 1936-1949.